Tau-targeting Treatment Slows Cognitive, Functional Declines: Trial

Alzheimer’s patients given the experimental tau-targeting therapy HMTM in a Phase 3 clinical trial experienced a substantially slower decline in cognitive and functional measures than would be expected based on published research, according to new findings announced by HMTM’s developer TauRx Pharmaceuticals. TauRx expects these results will…

Lower Levels of Tau Marker Seen With Aduhelm in Phase 3 Trials

Treatment with Aduhelm (aducanumab) showed a significant correlation with lower blood levels of p-tau181, a disease biomarker, and lesser cognitive and functional decline in Alzheimer’s patients, according to a recent data analysis of two Phase 3 clinical trials. The data, analyzed from around 7,000 blood samples collected from more than…

Preventing Bias Against People With Alzheimer’s Disease

Ageism is brutal, especially when combined with a misunderstanding of dementia. Somehow, rude people forget that they will one day get old. If we’re fortunate, growing older is the road ahead for us all. It should be everyone’s goal, since growing older is better than the alternative. With this in…